Who Can Be A Defendant In Biosimilar Patent Litigation?

by Fish & Richardson

Fish & Richardson

Can a party that did not submit an abbreviated biologics license application or an abbreviated new drug application, but will market the biosimilar or generic product after U.S. Food and Drug Administration approval, be sued for patent infringement or for a declaratory judgment alleging future infringement?

This question is pending before the U.S. District Court for the District of New Jersey in Amgen Inc. v. Adello Biologics LLC, where co-defendants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals Inc. seek dismissal, alleging that Amgen failed to state a claim under Federal Rule of Civil Procedure 12(b)(6) and further, because subject matter jurisdiction is lacking under FRCP 12(b)(1).[1]

Amgen’s complaints allege that Adello Biologics LLC infringed under Section 271(e)(2)(C) of the Patent Act by submitting an aBLA to manufacture a biosimilar of Amgen’s Neupogen.[2] Amgen further alleges that Amneal will infringe under Section 271(g) by importing and selling the biosimilar, which Adello manufactures using processes allegedly covered by Amgen’s patents.

In its motion to dismiss, Amneal argues that Amgen fails to state a claim for infringement under Section 271(e)(2)(C) because Amneal did not “submit” the Neupogen aBLA. Amneal further argues that there is no “current case or controversy of sufficient immediacy and reality” to support jurisdiction over a declaratory judgment action because it will only be responsible for the future “marketing, selling and pricing” of the accused biosimilar after FDA approval.[3]

After examining the different types of conduct that could trigger and support a Biologics Price Competition and Innovation Act or ANDA litigation, we examine the arguments presented in Amneal’s and Amgen’s briefs.

Submission of an aBLA or ANDA Is an “Act of Infringement”

The submission of an aBLA — like the submission of an ANDA — is an “artificial act of infringement” allowing a patent owner to file suit.[4] But against whom can it file?

Amneal did not submit the aBLA for Neupogen, and argues that it did not infringe under this provision. In support, it cites the U.S. Supreme Court’s statements in Sandoz Inc. v. Amgen Inc. that “[t]he complex statutory scheme [of the BPCIA] establishes processes both for obtaining FDA approval of biosimilars and for resolving patent disputes between manufacturers of licensed biologics and manufacturers of biosimilars.”[5] According to Amneal, this “carefully calibrated scheme” limits actions for infringement to “submitters,” and it therefore is not an infringer.[6]

Although only Adello submitted the aBLA, courts have held that multiple parties can be “submitters.” For example, in Cephalon Inc. v. Watson Pharmaceuticals Inc., both Watson Pharmaceuticals and Watson Pharma Inc., its whollyowned subsidiary, “took part in preparing the ANDA,” as “employees of each prepared and executed ANDA-related documents.”[7] The court held that both defendants “submitted” the ANDA. Other decisions have also relied on the corporate relationship between two affiliates in holding that both “submitted” an ANDA.[8]

One factor to consider in evaluating who submits an FDA application is whether the purported “submitter” will benefit from FDA approval. In In re Rosuvastatin Calcium Patent Litigation, Apotex Corp., the U.S. subsidiary of Apotex Inc., “signed and filed” an ANDA on behalf of Apotex Inc. The paragraph IV certification, however, was made by Apotex Inc. Astra Zeneca filed suit against Apotex Corp. — and not Apotex Inc.[9]

Apotex Corp. moved to dismiss, arguing it did not submit the ANDA within the meaning of Section 271(e)(2)(A). The court denied the motion, finding that Apotex Corp. was a “submitter” because it “filed the ANDA and actively participated with Apotex Inc. in preparation of the ANDA, and [it] intend[ed] to directly benefit from the ANDA by selling the drug product in the United States … upon approval of the ANDA.”[10] Although a parent-subsidiary relationship existed between defendants, the U.S. Court of Appeals for the Federal Circuit emphasized the relevance of future marketing and sale of the generic product in finding jurisdiction.[11]

Here, Amneal did not submit the Neupogen aBLA, because it did not commit an act of infringement under Section 271(e)(2)(C). And yet although it does not have a corporate relationship with Adello, Amneal will “benefit directly” if Adello’s aBLA is approved. The question is whether this fact should be considered and if so, is it enough to establish a case or controversy supporting jurisdiction?

Inducement of Infringement Under Section 271(b)

Amgen did not assert a claim of inducement under Section 271(b) against Amneal.[12] The Federal Circuit, however, has recognized that inducement claims are possible in Hatch-Waxman actions. But in most instances the inducement claim was lodged against the ANDA filer — not a third party such as Amneal.[13]

Inducement of Filing an FDA Application

In Shire LLC v. Amneal Pharmaceuticals LLC, the Federal Circuit held that conduct that merely assists another party in filing an ANDA is protected by the Hatch-Waxman safe harbor, 35 U.S.C. § 271(e)(1).[14] There, the court held that Johnson Matthey, which supplied the active ingredient to Amneal to allow it to file an ANDA, was not liable because “these sales and the ANDA defendants use of the API for filing the ANDA were … protected by the safe harbor of § 271(e)(1).”[15]

Inducement of Future Commercial Conduct

Inducement claims have been allowed against non-related entities that will supply and market an infringing product after FDA approval. For example, in Cephalon Inc. v. Watson Pharmaceuticals Inc., the district court sustained inducement claims lodged against related defendants and recognized that future “manufacturing, marketing or selling” was relevant. [16] Moreover, in SmithKline Beecham Corp v. Geneva Pharmaceuticals Inc., the court permitted SmithKline to amend its complaint to add Sumika, a third party that would manufacture and sell the generic product after FDA approval.[17]

The Federal Circuit specifically addressed inducement by third parties in Forest Laboratories Inc. v. Ivax Pharmaceuticals Inc.[18] There, Forest sued Ivax, the ANDA filer, and Cipla, the intended supplier of the generic drug, after FDA approval. The court enjoined both Ivax and Cipla from making, using, and selling the generic drug because the arrangement between the two “was undoubtedly a cooperative venture, and Cipla was to manufacture and sell infringing products to Ivax for resale in the United States.”[19] As particularly relevant here, the court held that the defendants were “partners.”[20]

Here, Amneal will not manufacture — but only sell — the Neupogen biosimilar. But since courts have allowed claims for inducement of future conduct after FDA approval,[21] it is conceivable that Amgen could have alleged an inducement claim against Amneal.

Declaratory Judgment Actions Based on Future Conduct

Amgen and Amneal dispute whether jurisdiction in a declaratory judgment action can be based solely on the future marketing and sales by the accused defendant. Amneal stresses the lack of an actual controversy of “sufficient immediacy” to warrant a declaratory judgment, while Amgen argues that allowing the actions to proceed against Adello and Amneal will promote judicial economy and efficiency since both actions have critical facts in common.

Amneal Argues That No Justiciable Controversy Exists

Amneal stresses the lack of an actual controversy of “sufficient immediacy” to warrant declaratory relief.[22] Citing Sandoz, it argues that allowing Amgen’s action to proceed “would upend the complex statutory scheme Congress established on the BPCIA for litigating biosimilar cases,”[23] especially because Adello’s aBLA has not been approved.[24] In other words, “[t]hat Amneal might someday infringe” does not satisfy the case or controversy requirement.[25]

Stressing the absence of FDA approval, Amneal cites Abbott Diabetes Care Inc. v. DexCom Inc., where the court dismissed Abbotts’s declaratory judgment claim because “the absence of FDA approval is evidence that the dispute between the parties is neither real nor immediate.”[26] But although the court dismissed the declaratory judgment claim in Abbott, it still addressed the merits of dispute; it did not dismiss the direct infringement claim because the defendant had exhibited two purported infringing devices at a trade show.[27]

Amneal also cites In re Rosuvastatin Calcium Patent Litigation, where a declaratory judgment action for infringement was dismissed while the action under Section 271(e)(2) proceeded.[28] Because the Hatch-Waxman 30-month stay precluded imminent marketing of the generic product, dismissal of the declaratory judgment claim in In re Rosuvastatin had little, if any, effect on resolving the pending dispute.[29]

Amneal next cites Eisai Co. Ltd. v. Mutual Pharmaceutical Co. Inc.,[30] Reckitt Benckiser Pharmaceutical Inc. v. Biodelivery Sciences, Internaional Inc.,[31] and Abbott Laboratories v. Zenith Laboratories, Inc.[32] where declaratory judgment actions were dismissed.[33] But in Eisai and Reckitt, paragraph IV certifications were lacking, and thus no actions were proper under Section 271(e)(2). This apparently influenced the courts to dismiss the declaratory judgment actions as well. In Abbott, the asserted patent was not listed in the Orange Book when the ANDA was filed and therefore, Abbott could not assert a Section 271(e)(2) claim. Allowing the declaratory judgment claim to proceed in that case could have undermined the Hatch-Waxman procedure.

In sum, Amneal alleges that Amgen’s claims “are based entirely on speculation about what Amneal may do sometime in the future,” and “[t]hese types of forward–facing allegations” do not support a claim for infringement, much less a declaratory judgment action.[34]

But Amneal’s criticism of the forward-looking nature of Amgen’s allegations may not have fully considered the “real world” aspects of Hatch-Waxman or BPCIA litigation, which allows infringement actions even though no actual infringement has occurred. In this regard, the Federal Circuit and district courts have recognized that a generic’s “future intended acts” determine both personal jurisdiction and venue in Hatch-Waxman actions. The authors recognize that determinations of venue and personal jurisdiction are distinct from subject matter jurisdiction. But should future conduct at least be considered in determining whether a present case or controversy exists?

In Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.,[35] the Federal Circuit held that personal jurisdiction in Hatch-Waxman actions exists wherever a defendant intends to market a generic product after FDA approval. In its decision, the court specifically considered “the real-world actions for which approval is sought,” i.e., the “manufacture, use or sale of the new drug for which the application is submitted.”[36]

Indeed, the Federal Circuit had previously noted that an infringement inquiry under the Hatch-Waxman Act is “whether, if a particular drug were put on the market, it would infringe the relevant patent.”[37] The Supreme Court has also recognized the forward-looking nature of the Hatch-Waxman Act, stating that an “act of infringement [under § 271(e)(2)] … consists of submitting an ANDA … containing … [a] certification that is in error as to whether commercial manufacture, use, or sale of the new drug (none of which, of course, has actually occurred) violates the relevant patent.”[38]

As to venue, the U.S. District Court for the District of Delaware in Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., held that venue exists wherever the defendant intends to market its generic product after FDA approval.[39] As in Accorda, “intended, planned future (after FDA approval) acts” were considered crucial:

In the Court’s view, the best, most reasonable conclusion after Acorda is that an ANDA filer’s future, intended acts must be included as part of the “acts of infringement” analysis for purposes of determining if venue is proper under the patent venue stature. In Acorda, the Federal Circuit plainly held that intended, planned future (after FDA approved) are acts that must be considered now in determining [jurisdiction in Hatch Waxman actions].[40]

The question remains whether such post-approval conduct should be considered in determining jurisdiction in declaratory judgment actions.[41]

Amgen Argues That Judicial Efficiency Warrants Sustaining Both Actions

Amgen does not contend that Amneal violated the BPCIA, but rather seeks a declaratory judgment that Amneal infringes or will infringe under Section 271(g) by offering to sell or selling the accused biosimilar made by processes covered by Amgen’s patents.[42]

Amgen contends that a justiciable controversy exists because: (1) clinical trials for the Neupogen biosimilar have been completed; (2) an aBLA was filed; (3) a notice of intent to market was served; and (4) Amneal will be Adello’s exclusive licensee to price, market, and sell the biosimilar in the U.S.[43] Amgen emphasizes these factors to distinguish cases cited by Amgen because the defendants in those cases had not reached the advanced stage of market introduction that Amneal had, and thus had no created a case or controversy to support jurisdiction.

Amgen disputes Amneal’s argument that “no immediate controversy” exists because the FDA has not yet approved the Neupogen biosimilar, arguing that the Federal Circuit and many district courts have allowed declaratory judgment claims to accompany Section 271(e)(2) claims.[44] But in the cited cases, both claims were asserted against the same defendant or against a party that itself had committed an act of infringement supporting jurisdiction.[45]

For instance, in Glaxo Inc. v. Novopharm Ltd., the court allowed Glaxo to file a declaratory judgement action for infringement under Section 271(g) even thought the ANDA was not yet approved and the generic product would not launch for 18 months.[46] In denying Novopharm’s motion to dismiss, the court stated that “the threat of Novopharm entering the U.S. market was not ‘years away’ nor was there doubt that Novopharm wished to sell some form of [the accused] product.”[47] While the language certainly supports Amgen’s position, Novopharm had committed an act of infringement under Section 271(e)(2). Thus, the declaratory judgment claim was an “add-on,” unlike here, where it is the only claim against Amneal.

Amgen criticizes Amneal’s reliance on Takeda Pharmaceutical Co. v. Mylan, Inc.,[48] where the court dismissed a declaratory judgment action as duplicating similar claims lodged against the same party — which is “completely different from the situation here where claims are being asserted against different parties.”[49] But the difference between asserting declaratory judgment and infringement claims against the same party versus asserting only a declaratory judgment claim against a third-party (as here) is significant. And Amgen’s cited cases must be reviewed in that light.

In sum, Amgen’s principal argument is that the substantial overlap between the two actions warrants denying Amneal’s motion. For example, Amgen argues that it must prove that Adello infringes by practicing processes covered by Amgen’s patents, whereas it must prove that Amneal infringes or will infringe by selling or offering to sell the product manufactured by those same processes.[50] According to Amgen, this “common element” demonstrates that whether Adello’s manufacturing process infringes Amgen’s patents is key to both actions. It argues that allowing both to proceed will therefore promote judicial economy and efficiency.[51] One could argue, however, that Amgen’s judicial economy argument is somewhat questionable because if Amgen proved that Adello’s processes infringed in a separate action, Amneal would be hard pressed to proceed with its defense, even if it were not barred by the prior judgment.


A clear answer to the precise question — whether the future marketing and sale of a biosimilar drug is sufficient to establish declaratory judgment jurisdiction — is pending in the District of New Jersey.

Decisions stressing the relevance of future “marketing and distribution” in inducement actions (e.g., Cephalon) or the recognition that an ANDA submitter and its distributor exhibit a “cooperative venue” or are even “partners” (e.g., Forest Labs) were not cited in the briefs. At a minimum, these decisions accentuate the close commercial relationship between an FDA “submitter” and its future “distributor,” and may be worthy of consideration.

Recent decisions emphasizing “the real world actions” and consequences of Hatch-Waxman litigations (e.g., Acorda) could also be pertinent. If “planned future conduct” and “intended acts” “must” be considered in determining an “act of infringement” under Section 271(e)(2) (e.g., Bristol-Myers), they may also be relevant in determining jurisdiction of declaratory judgment claims.

We await the court’s decision on this important yet unsettled, issue addressing jurisdiction in declaration judgment actions filed by a patent owner against a biosimilar or ANDA defendant.

[1] Amgen Inc. and Amgen Mfg., Ltd. v. Adello Biologics, LLC, Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals, Inc., C.A. No. 2:18-cv-03347-CCC-MF (D.N.J.).

[2] As relevant here, the initial and amended complaints are equivalent.

[3] Defendants Amneal Pharmaceuticals LLC’s and Amneal Pharmaceuticals, Inc.’s Brief in Support of Motion to Dismiss the Claims Against Them in First Amended Complaint (“Amneal Brief”) at 3-4. (citation omitted). Portions of Amgen’s opposition and Amneal’s reply are redacted, and their possible effect the outcome of the motion are necessarily not discussed herein.

[4] 35 U.S.C. § 271(e)(2)(C). (“It shall be an act of infringement to submit . . . an application for approval of a biological product . . . .”). Most cases discussed herein relate to ANDA litigation, but the holdings are equally applicable to BPCIA litigation.

[5] Amneal Brief at 3-4 (quoting Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664, 1669 (2017) (emphasis in original) (internal quotes omitted)).

[6] Id. at 4-5.

[7] Cephalon, Inc. v. Watson Pharmaceuticals, Inc. , 629 F. Supp. 2d 338, 349 (D. Del. 2009).

[8] See, e.g., Wyeth v. Lupin Ltd. , 505 F. Supp. 2d 303 (D. Md. 2007); Aventis Pharma Deutschland GMBH v. Lupin Ltd. , 403 F. Supp. 2d 484 (E.D. Va. 2005); Novo Nordisk A/S v. Caraco Pharma. Labs., Ltd. , 450 F. Supp. 2d 757 (E.D. Mich. 2006).

[9] Apotex Canada was not a party to this suit only because, at its request, the infringement case against Apotex Canada was transferred to the Southern District of Florida.

[10] 703 F.3d 511, 527 (Fed. Cir. 2012).

[11] Id. at 528 n.20 (citation omitted). In a concurring opinion, Judge Plager opined that the real party-in-interest is the “commercial manufacturer,” who is the entity that “submits” the application and thus commits an act of infringement. Id. at 529, 530 (Plager, J., concurring).

[12] In its reply brief, Amneal notes this fact in distinguishing various cases cited by Amgen. Defendants Amneal Pharmaceuticals LLC’s and Amneal Pharmaceuticals, Inc.’s Reply in Support of Motion to Dismiss the Claims Against Them in the Second Amended Complaint (“Amneal Reply”) at 12 n.2.

[13] See, e.g., Allergan, Inc. v. Alcon Labs., Inc. , 324 F.3d 1322 (Fed. Cir. 2003); Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003).

[14] Shire LLC v. Amneal Pharmaceuticals, LLC , 802 F.3d 1301 (Fed. Cir. 2015).

[15] Id. at 1310. Before Shire, confusion existed regarding induced infringement in Hatch-Waxman actions. Some courts held that assisting in an ANDA filing was protected by the safe harbor. See Astra Zeneca AB v. Mylan Labs., Inc. , 265 F. Supp. 2d 213, 217-18 (S.D.N.Y 2003) (proposed defendants supplied API and other technical information to ANDA filer); Pfizer Inc. v. Ranbaxy Labs., Ltd. , 321 F. Supp. 2d 612, 618 (D. Del. 2004) (Safe Harbor applied even though proposed defendant and ANDA filer enjoyed a parent-subsidiary relationship); Ortho-McNeil Pharma., Inc. v. Mylan Labs., Inc. , 267 F. Supp. 545, 548-49 (N.D.W. Va. 2003) (supplying API to ANDA filer is protected by safe harbor). Others courts disagreed. See, e.g., SmithKline Beecham Corp. v. Pentech Pharms., Inc. , 2001 WL 184804 (N.D. Ill. 2001) (proposed defendant participated in research for and the filing of ANDA).

[16] Cephalon, Inc. v. Watson Pharmaceuticals, Inc, 629 F. Supp. 2d 338, 350 (D. Del. 2009).

[17] 287 F. Supp. 2d 576, 585 (E.D. Pa. 2002). Sumika had filed the Drug Master File for the generic product and authorized Genera to rely on it. See also SmithKline Beecham Corp. v. Pentech Pharms., Inc. , 2001 WL 184804, *7 (N.D. Ill. Feb. 20, 2001); Wyeth v. Lupin Ltd. , 505 F. Supp. 2d 303, 308 (D. Md. 2007); Aventis Pharma Deutschland GMBH v. Lupin Ltd. , 403 F. Supp. 2d 484, 495 (E.D. Va. 2005).

[18] Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc. , 501 F.3d 1263 (Fed. Cir. 2007).

[19] Id. at 1272.

[20] Id.

[21] See Gilead Scis., Inc. v. Teva Pharms., Inc. , 2011 WL 2462764 (S.D.N.Y. June 3, 2011); In re Cyclobenzaprine Hydrochloride Extended-Release Capsules Patent Litig ., 693 F. Supp. 2d 409, 418 (D. Del. 2010).

[22] Amneal Brief at 10-11. Moreover, even if declaratory judgment jurisdiction were present, Amneal argues that jurisdiction should be declined. Id. at 16-19. In its reply, Amneal stresses the same argument. Amneal Reply at 13-15.

[23] Amneal Brief at 11.

[24] Id. at 12.

[25] Amneal Reply at 3-4 (emphasis in original).

[26] Abbott Diabetes Care, Inc. v. DexCom, Inc. , 2006 WL 2375035 at *3 n.3 (D. Del. Aug. 16, 2006).

[27] Id. at *5.

[28] In re Rosuvastatin Calcium Patent Litigation , 2008 WL 5046424 at *13 (D. Del. Nov. 24, 2008).

[29] Id. at *12.

[30] Eisai Co., Ltd. v. Mutual Pharmaceutical Co., Inc. , 2007 WL 4556958 (D.N.J. Dec. 20, 2007).

[31] Reckitt Benckiser Pharmaceutical, Inc. v. Biodelivery Sciences, Int’l, Inc. , 2014 WL 2119822 (E.D.N.C. May 20, 2014).

[32] Abbott Laboratories v. Zenith Laboratories, Inc. , 934 F. Supp. 925 (N.D. Ill. 1995).

[33] Amneal Brief at 15-16.

[34] Id. at 6.

[35] Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc. , 817 F.3d 755 (Fed. Cir. 2016).

[36] Id. at 760.

[37] Bristol-Myers Squibb Co. v. Royce Labs, Inc. , 69 F.3d 1130, 1135 (Fed. Cir. 1995) (emphasis in original). See also Sunovion Pharms., Inc. v. Teva Pharms. USA, Inc. , 731 F.3d 1271, 1278-79 (Fed. Cir. 2013) (the question is whether the product for which the ANDA filer seeks approval would infringe).

[38] Eli Lilly & Co. v. Medtronic, Inc. , 496 U.S. 661, 678 (1990).

[39] 2017 WL 3980155.

[40] Id. at *23-*24. At least one court has disagreed with the Bristol analysis. See Galderma Labs., LP v. Teva Pharms. USA, Inc. , 2017 WL 6505793 (N.D. Tex. Nov. 17, 2017).

[41] See generally Forest Labs., 501 F.3d at 1272; SmithKline Beecham, 287 F. Supp. 2d at 585.

[42] See Amgen’s Memorandum of Law in Opposition to Amneal’s Motion to Dismiss (“Amgen’s Brief”) at 2. Amgen’s allegations that Amneal has already infringed are unclear as portions of the briefs are redacted.

[43] Id. at 20-23.

[44] Id. at 18-19, 26, 26 n.4.

[45] Amneal Reply at 12-13 n.2.

[46] Glaxo Inc. v. Novopharm, Ltd. , 110 F.3d 1562, 1571 (Fed. Cir. 1997).

[47] Id.

[48] Takeda Pharmaceutical Co. v. Mylan, Inc. , 62 F. Supp. 3d 1115 (N.D. Cal. 2014).

[49] Amgen Brief at 27.

[50] Id. at 24.

[51] Id.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Fish & Richardson | Attorney Advertising

Written by:

Fish & Richardson

Fish & Richardson on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.